Jon Napitupulu

Biogen has completed its acquisition of Alcyone Therapeutics, adding an implantable intrathecal drug delivery system, ThecaFlex DRx, to its...

Entera Bio secured FDA alignment that a single, 24‑month, multinational Phase 3 trial using change in total hip bone...

Inhibikase Therapeutics reported third-quarter 2025 results and set a near-term catalyst: the initiation of its Phase 2b IMPROVE-PAH study...

Tevogen Bio filed its Q3 2025 10-Q, reporting a GAAP operating loss of $5.7 million for the quarter, a...

Prelude Therapeutics outlined a 2026 clinical re-entry, built around two precision oncology assets: advancing a mutant-selective JAK2V617F JH2 allosteric...

Zenas Biopharma (Nasdaq: ZBIO) packed several catalysts into its latest update: topline data from the phase 3 Indigo trial...

Cosciens Biopharma has voluntarily delisted from Nasdaq, maintained its Toronto Stock Exchange listing, and is seeking quotation on the...

Opus Genetics reported a pivotal quarter for its inherited retinal disease portfolio, highlighting positive Phase 1/2 data for its...

Legend Biotech reported third-quarter 2025 results anchored by accelerating commercial momentum for Carvykti, including estimated net trade sales of...

TScan Therapeutics has secured FDA alignment on a pivotal trial design for TSC-101 in post-transplant hematologic malignancies, implemented a...